Research Topic

Cellular Therapies in Cancer

About this Research Topic

In this series, we provide our readers with the latest updates in the field of cellular therapies besides hematopoietic stem cell transplantation (HSCT). Various strategies for adoptive immunotherapy have been developed using a variety of lymphocytes. A vast majority of these involve αβ T cells or natural ...

In this series, we provide our readers with the latest updates in the field of cellular therapies besides hematopoietic stem cell transplantation (HSCT). Various strategies for adoptive immunotherapy have been developed using a variety of lymphocytes. A vast majority of these involve αβ T cells or natural killer (NK) cells, though γδ T cells and invariant NK-like T cells (iNKT) cells are also been explored. One of the major distinguishing features of these therapies is whether or not the effector cells undergo genetic modification prior to infusion. In the absence of genetic alteration, the use of conventional T or NK cells requires ex vivo expansion/activation to generate sufficient numbers of activated cells, followed in some cases by further in vivo cytokine stimulus to support persistence. Moreover, the conventional effector cells are polyclonal and not entirely antigen specific. Genetic modification imparts antigen-specificity to the cells, which then bind to the target cells with a higher affinity. Examples of such novel approaches include the genetically engineered T cell receptor (TCR) cells or chimeric antigen receptor (CAR) αβ- or γδ- T cells. Although the use of TCR-modified T cells has been limited mostly to treat solid tumors, therapies with CAR αβ T cells have shown tremendous success, especially in patients with high risk CD19 B-cell malignancies. Similarly, genetic modification of NK cells to create CAR-NK cells and the bispecific- and trispecific killer cell engagers (BiKEs/TriKEs) is also being implemented.

The source of effector cells is another factor that classifies adoptive immunotherapy into two broad categories. As allogeneic T cells can cause potentially fatal graft-versus host disease (GVHD), T cell-based adoptive immunotherapy almost always involves autologous cells. On the other hand, as the earlier trials of autologous NK cell therapies were disappointing and because NK cells do not cause GVHD, most of the NK cell immunotherapy trials are harvesting the cells from an allogeneic source.

With the depth of cellular therapies and the emerging cutting edge technology, this comprehensive review intends to provide an overview of its expansive applications.

This series intends to cover the advancements in the field of adoptive immunotherapy focusing on the following topics:
• Cellular therapies using αβ T cells
• Cellular therapies using γδ T cells
• Virus-specific T cells
• Cellular therapies using NK cells
• Cellular therapies using iNKT cells
• Genetically modified T cells, including CAR T cells and TCR-modified T cells
• Genetically modified NK cells, including CAR NK cells, BiKEs/TriKEs and iPSC-derived NK cells


Keywords: hematopoietic stem cell transplantation, CAR T cells, immunotherapy, αβ T cells, γδ T cells, Virus-specific T cells, Tumor infiltrating lymphocytes, invariant NK T cells


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

20 August 2017 Manuscript
15 January 2018 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

20 August 2017 Manuscript
15 January 2018 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top